Does Rallies show 13F holders for MLTX?

Yes. Rallies tracks hedge fund and 13F ownership data for MLTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MLTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MLTX. It does not provide personalized investment advice.

MLTX (MoonLake Immunotherapeutics Class A Ordinary Shares) Stock Analysis - Hedge Fund Holdings

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is a publicly traded Healthcare sector company. As of May 21, 2026, MLTX trades at $17.04 with a market cap of $1.21B and a P/E ratio of -4.82. MLTX moved +4.09% today. Year to date, MLTX is +52.37%; over the trailing twelve months it is -57.67%. Its 52-week range spans $5.95 to $62.75. Analyst consensus is buy with an average price target of $29.15. Rallies surfaces MLTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MLTX stock?

Hedge funds tracked by Rallies that own MLTX include Soros Fund, Duquesne Family, and Centerbook Partners. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MoonLake Immunotherapeutics Class A Ordinary Shares.

MLTX Key Metrics

Key financial metrics for MLTX
Metric	Value
Price	$17.04
Market Cap	$1.21B
P/E Ratio	-4.82
EPS	$-3.53
Dividend Yield	0.00%
52-Week High	$62.75
52-Week Low	$5.95
Volume	344
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-230.32M
Gross Margin	0.00%

Top Hedge Funds Holding MLTX

Soros Fund holds 100.00K shares of MLTX, changed +0.00% as of Dec 31, 2023.
Duquesne Family holds 87.50K shares of MLTX, changed +0.00% as of Mar 31, 2024.
Centerbook Partners holds 15.36K shares of MLTX, changed -47.20% as of Jun 30, 2024.

Latest MLTX News

MoonLake’s Sonelokimab Delivers 62% HiSCR75 Week 40 But Stock Plunges 88% — Mar 31, 2026
Sonelokimab Delivers 81% Response in Phase 2 Axial Spondyloarthritis Trial — Feb 23, 2026
MoonLake’s Sonelokimab Delivers 81% ASAS40 Response; $394M Cash Fund Runs Into H2 2027 — Feb 22, 2026
MoonLake Immunotherapeutics Sees 42.6% Price Target Cut to $10, Gains FDA BLA Clarity — Jan 15, 2026
MoonLake Shares Jump 9.6% After Goldman Sachs Downgrade and Positive FDA Feedback — Jan 15, 2026

Recent MLTX Insider Trades

Bodenstedt Matthias sold 13.65K (~$273.33K) on May 11, 2026.
Bodenstedt Matthias sold 2.43K (~$47.45K) on Apr 14, 2026.
Santos da Silva Jorge sold 51.87K (~$945.64K) on Apr 13, 2026.

MLTX Analyst Consensus

14 analysts cover MLTX: 0 strong buy, 10 buy, 2 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.15.

Common questions about MLTX

Who owns MLTX stock?: Hedge funds tracked by Rallies that own MLTX include Soros Fund, Duquesne Family, and Centerbook Partners. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MoonLake Immunotherapeutics Class A Ordinary Shares.
Does Rallies show 13F holders for MLTX?: Yes. Rallies tracks hedge fund and 13F ownership data for MLTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MLTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MLTX. It does not provide personalized investment advice.